Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients
✍ Scribed by Esther Voigt; Christian Schulz; Gerd Klausen; Joerg Goelz; Stefan Mauss; Guenther Schmutz; Heiko Jessen; Lutwin Weitner; Antonius Mutz; Dietmar Schranz; Juergen K. Rockstroh; for the KAAD study group
- Publisher
- Elsevier Science
- Year
- 2006
- Tongue
- English
- Weight
- 162 KB
- Volume
- 53
- Category
- Article
- ISSN
- 0163-4453
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
accurate representation of the data is given in Table 1. 7. The major conclusion of this paper was that monitoring hepatitis C virus RNA levels and varying the duration of therapy can save resources without sacrificing rates of SVR. The authors used the Blackwelder test to test the noninferiority of
for the amfAR DCRI 010 Study Group Human immunodeficiency virus (HIV)-infected patients increasingly experience the consequences of chronic hepatitis C virus (HCV) coinfection. This trial randomized 107 patients coinfected with HIV and HCV to receive 48 weeks of interferon alfa-2b (IFN) 3 million un